Kavi Devraj

Goethe University Frankfurt — Germany

Neuroscience · Life Sciences

27h-index3.3kcitations82works11.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Barrier Structure and Function Studies(20), Cancer, Hypoxia, and Metabolism(17), Glioma Diagnosis and Treatment(11), Angiogenesis and VEGF in Cancer(11), Cancer Research and Treatments(10)

Publications82 total

Regulation of the blood-brain barrier function by peripheral cues in health and disease
Metabolic Brain Disease·2024· 6 citedOpen Access
Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis
Neuro-Oncology·2024· 8 citedOpen Access
Fatty acid-binding protein 5 is a functional biomarker and indicator of ferroptosis in cerebral hypoxia
Cell Death and Disease·2024· 21 citedOpen Access
Bioinformatics for wet-lab scientists: practical application in sequencing analysis
BMC Genomics·2023· 13 citedOpen Access
Movie 4 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 3 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie 1 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 4 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 4 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie 3 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie Legends from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Movie Legends from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Tables from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Data from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure 3 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
Supplementary Figure Legends from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Stefan Liebner(23), Karl H. Plate(13), Jadranka Macas(12), Yvonne Reiss(11), Patrick N. Harter(9), Michel Mittelbronn(8), Daniel Spitzer(8), Sylvaine Guérit(8), Stefan Günther(7), Kathleen Sommer(6), Mariangela Di Tacchio(5), Rajkumar Vutukuri(5), Waltraud Pfeilschifter(5), Thomas M. Freiman(4), Stefanie Dimmeler(4), Ian A. Simpson(4), Jenny Zinke(4), Cathrin J. Czupalla(4), Maryam I. Khel(4), Xiaoxiong Jia(4)